{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:41:25Z","timestamp":1793727685026,"version":"4.6.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2006,9,20]],"date-time":"2006-09-20T00:00:00Z","timestamp":1158710400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1007\/s00415-006-0218-8","type":"journal-article","created":{"date-parts":[[2006,9,20]],"date-time":"2006-09-20T11:07:44Z","timestamp":1158750464000},"page":"1337-1341","source":"Crossref","is-referenced-by-count":136,"title":["Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain"],"prefix":"10.1007","volume":"253","author":[{"given":"J\u00f6rg","family":"Wissel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Haydn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Brenneis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Poewe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludwig D.","family":"Schelosky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,9,20]]},"reference":[{"key":"218_CR1","doi-asserted-by":"crossref","unstructured":"Shakespeare DT, Boggild M, Young C (2003) Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst RevCD001332","DOI":"10.1002\/14651858.CD001332"},{"issue":"iii","key":"218_CR2","first-page":"ix","volume":"7","author":"S Beard","year":"2003","unstructured":"Beard S, Hunn A, Wight J (2003) Treatments for spasticity and pain in multiple sclerosis: a systematic review. Health Technol Assess 7:iii, ix\u2013iii, 111","journal-title":"Health Technol Assess"},{"key":"218_CR3","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/brain\/awg143","volume":"126","author":"L Iversen","year":"2003","unstructured":"Iversen L (2003) Cannabis and the brain. Brain 126:1252\u20131270","journal-title":"Brain"},{"key":"218_CR4","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1096\/fj.00-0399fje","volume":"15","author":"D Baker","year":"2001","unstructured":"Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Makriyannis A, Khanolkar A, Layward L, Fezza F, Bisogno T, Di MV (2001) Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J 15:300\u2013302","journal-title":"FASEB J"},{"key":"218_CR5","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S0091-3057(03)00127-8","volume":"75","author":"G Diana","year":"2003","unstructured":"Diana G, Malloni M, Pieri M (2003) Effects of the synthetic cannabinoid nabilone on spatial learning and hippocampal neurotransmission. Pharmacol Biochem Behav 75:585\u2013591","journal-title":"Pharmacol Biochem Behav"},{"key":"218_CR6","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/cpt197722185","volume":"22","author":"A Rubin","year":"1977","unstructured":"Rubin A, Lemberger L, Warrick P, Crabtree RE, Sullivan H, Rowe H, Obermeyer BD (1977) Physiologic disposition of nabilone, a cannabinol derivative, in man. Clin Pharmacol Ther 22:85\u201391","journal-title":"Clin Pharmacol Ther"},{"key":"218_CR7","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/bjc.1983.247","volume":"48","author":"S Ahmedzai","year":"1983","unstructured":"Ahmedzai S, Carlyle DL, Calder IT, Moran F (1983) Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy. Br J Cancer 48:657\u2013663","journal-title":"Br J Cancer"},{"key":"218_CR8","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2165\/00003495-198530020-00002","volume":"30","author":"A Ward","year":"1985","unstructured":"Ward A, Holmes B (1985) Nabilone. A preliminary review of its pharmacological properties and therapeutic use. Drugs 30:127\u2013144","journal-title":"Drugs"},{"key":"218_CR9","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/hup.688","volume":"20","author":"I Kurzthaler","year":"2005","unstructured":"Kurzthaler I, Bodner T, Kemmler G, Entner T, Wissel J, Berger T, Fleischhacker WW (2005) The effect of nabilone on neuropsychological functions related to driving ability: an extended case series. Hum Psychopharmacol 20:291\u2013293","journal-title":"Hum Psychopharmacol"},{"key":"218_CR10","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0885-3924(00)00146-9","volume":"20","author":"J Wissel","year":"2000","unstructured":"Wissel J, Muller J, Dressnandt J, Heinen F, Naumann M, Topka H, Poewe W (2000) Management of spasticity associated pain with botulinum toxin A. J Pain Symptom Manage 20:44\u201349","journal-title":"J Pain Symptom Manage"},{"key":"218_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF02190083","volume":"240","author":"M Maurer","year":"1990","unstructured":"Maurer M, Henn V, Dittrich A, Hofmann A (1990) Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial. Eur Arch Psychiatry Clin Neurosci 240:1\u20134","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"218_CR12","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0140-6736(95)90485-9","volume":"345","author":"CN Martyn","year":"1995","unstructured":"Martyn CN, Illis LS, Thom J (1995) Nabilone in the treatment of multiple sclerosis. Lancet 345:579","journal-title":"Lancet"},{"key":"218_CR13","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/S0140-6736(98)05429-4","volume":"353","author":"W Hamann","year":"1999","unstructured":"Hamann W, di Vadi PP (1999) Analgesic effect of the cannabinoid analogue nabilone is not mediated by opioid receptors. Lancet 353:560","journal-title":"Lancet"},{"key":"218_CR14","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/S0140-6736(03)14738-1","volume":"362","author":"J Zajicek","year":"2003","unstructured":"Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A (2003) Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 362:1517\u20131526","journal-title":"Lancet"},{"key":"218_CR15","doi-asserted-by":"crossref","first-page":"413S","DOI":"10.1002\/j.1552-4604.1981.tb02621.x","volume":"21","author":"DJ Petro","year":"1981","unstructured":"Petro DJ, Ellenberger C Jr. (1981) Treatment of human spasticity with delta 9-tetrahydrocannabinol. J Clin Pharmacol 21:413S\u2013416S","journal-title":"J Clin Pharmacol"},{"key":"218_CR16","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/BF00314410","volume":"236","author":"HM Meinck","year":"1989","unstructured":"Meinck HM, Schonle PW, Conrad B (1989) Effect of cannabinoids on spasticity and ataxia in multiple sclerosis. J Neurol 236:120\u2013122","journal-title":"J Neurol"},{"key":"218_CR17","first-page":"446","volume":"34","author":"R Brenneisen","year":"1996","unstructured":"Brenneisen R, Egli A, Elsohly MA, Henn V, Spiess Y (1996) The effect of orally and rectally administered delta 9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. Int J Clin Pharmacol Ther 34:446\u2013452","journal-title":"Int J Clin Pharmacol Ther"},{"key":"218_CR18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1300\/J251v07n01_04","volume":"7","author":"JT Ungerleider","year":"1987","unstructured":"Ungerleider JT, Andyrsiak T, Fairbanks L, Ellison GW, Myers LW (1987) Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse 7:39\u201350","journal-title":"Adv Alcohol Subst Abuse"},{"key":"218_CR19","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/clpt.1994.33","volume":"55","author":"HS Greenberg","year":"1994","unstructured":"Greenberg HS, Werness SA, Pugh JE, Andrus RO, Anderson DJ, Domino EF (1994) Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. Clin Pharmacol Ther 55:324\u2013328","journal-title":"Clin Pharmacol Ther"},{"key":"218_CR20","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1097\/00045391-199510000-00012","volume":"2","author":"RW Kogel","year":"1995","unstructured":"Kogel RW, Johnson PB, Chintam R, Robinson CJ, Nemchausky BA (1995) Treatment of Spasticity in Spinal Cord Injury with Dronabinol, a Tetrahydrocannabinol Derivative. Am J Ther 2:799\u2013805","journal-title":"Am J Ther"},{"key":"218_CR21","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1212\/WNL.58.9.1404","volume":"58","author":"J Killestein","year":"2002","unstructured":"Killestein J, Hoogervorst EL, Reif M, Kalkers NF, Van Loenen AC, Staats PG, Gorter RW, Uitdehaag BM, Polman CH (2002) Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 58:1404\u20131407","journal-title":"Neurology"},{"key":"218_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-200464010-00001","volume":"64","author":"J Killestein","year":"2004","unstructured":"Killestein J, Uitdehaag BM, Polman CH (2004) Cannabinoids in multiple sclerosis: do they have a therapeutic role? Drugs 64:1\u201311","journal-title":"Drugs"},{"key":"218_CR23","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1056\/NEJMp058165","volume":"353","author":"S Okie","year":"2005","unstructured":"Okie S (2005) Medical Marijuana and the Supreme Court. N Engl J Med 353:648\u2013651","journal-title":"N Engl J Med"},{"key":"218_CR24","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0163-7258(02)00255-3","volume":"95","author":"RG Pertwee","year":"2002","unstructured":"Pertwee RG (2002) Cannabinoids and multiple sclerosis. Pharmacol Ther 95:165\u2013174","journal-title":"Pharmacol Ther"},{"key":"218_CR25","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1006\/nbdi.1998.0220","volume":"5","author":"P Consroe","year":"1998","unstructured":"Consroe P (1998) Brain cannabinoid systems as targets for the therapy of neurological disorders. Neurobiol Dis 5:534\u2013551","journal-title":"Neurobiol Dis"},{"key":"218_CR26","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S1474-4422(03)00381-8","volume":"2","author":"D Baker","year":"2003","unstructured":"Baker D, Pryce G, Giovannoni G, Thompson AJ (2003) The therapeutic potential of cannabis. Lancet Neurol 2:291\u2013298","journal-title":"Lancet Neurol"},{"key":"218_CR27","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0301-0082(00)00031-9","volume":"63","author":"RG Pertwee","year":"2001","unstructured":"Pertwee RG (2001) Cannabinoid receptors and pain. Prog Neurobiol 63:569\u2013611","journal-title":"Prog Neurobiol"},{"key":"218_CR28","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1006\/nbdi.1998.0220","volume":"5","author":"P Consroe","year":"1998","unstructured":"Consroe P (1998) Brain cannabinoid systems as targets for the therapy of neurological disorders. Neurobiol Dis 5:534\u2013551","journal-title":"Neurobiol Dis"},{"key":"218_CR29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/bmj.323.7303.13","volume":"323","author":"FA Campbell","year":"2001","unstructured":"Campbell FA, Tramer MR, Carroll D, Reynolds DJ, Moore RA, McQuay HJ (2001) Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 323:13\u201316","journal-title":"BMJ"},{"key":"218_CR30","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S1090-3801(03)00084-3","volume":"8","author":"N Attal","year":"2004","unstructured":"Attal N, Brasseur L, Guirimand D, Clermond-Gnamien S, Atlami S, Bouhassira D (2004) Are oral cannabinoids safe and effective in refractory neuropathic pain? Eur J Pain 8:173\u2013177","journal-title":"Eur J Pain"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-006-0218-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-006-0218-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-006-0218-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T15:04:09Z","timestamp":1559055849000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-006-0218-8"}},"subtitle":["A double-blind placebo-controlled cross-over trial"],"short-title":[],"issued":{"date-parts":[[2006,9,20]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["218"],"URL":"https:\/\/doi.org\/10.1007\/s00415-006-0218-8","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,9,20]]}}}